1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Jeremy Steele from Control Bionics (ASX:CBL) shares that the company secures agreements in two major markets. The company invests in NeuroBounce, aiming to enhance jump training for athletes using their EMG technology. The goal is to bring this program to Australia.
Jeremy mentions a memorandum with Stroke Lab in Tokyo. This collaboration involves using Control Bionics' technology to improve rehabilitation for stroke and other neurological conditions. The plan is to introduce the NeuroStrip technology to Japan and eventually Australia.
Control Bionics (ASX:CBL) gains a 20% stake in NeuroBounce, introducing a subscription-based model. This includes upfront costs for equipment and recurring revenue through software and athlete fees. Jeremy highlights this shift towards more sustainable revenue streams.
